Corline Biomedical Q4: Focus on Kardium’s market launch - Redeye
Redeye provides an update following Corline’s Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.
ANNONS
Redeye provides an update following Corline’s Q4 2024 report. The report itself was relatively undramatic; however, we look forward to an eventful 2025. We make some model changes, but our fair value range remains intact.